LinkedIn Profile

Access Theravance Biopharma historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:tbph 5558032 Apr 28th, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 28th, 2024 12:04AM Apr 28th, 2024 12:04AM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 27th, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 26th, 2024 11:43PM Apr 26th, 2024 11:43PM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 26th, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 25th, 2024 11:51PM Apr 26th, 2024 09:12AM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 25th, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 24th, 2024 11:45PM Apr 25th, 2024 07:24PM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 24th, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 23rd, 2024 11:54PM Apr 24th, 2024 11:54AM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 23rd, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 22nd, 2024 11:35PM Apr 22nd, 2024 11:35PM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 22nd, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 22nd, 2024 12:26AM Apr 22nd, 2024 12:26AM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 21st, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 21st, 2024 03:20AM Apr 21st, 2024 03:20AM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 20th, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 20th, 2024 12:10AM Apr 20th, 2024 05:42PM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology
nasdaq:tbph 5558032 Apr 19th, 2024 12:00AM Theravance Biopharma US, Inc. 7.5K 196.00 Open Apr 19th, 2024 04:43AM Apr 19th, 2024 04:43AM Theravance Biopharma aims to transform the treatment of specialty respiratory and neurologic diseases by delivering Medicines that Make a Difference® in patients’ and caregivers’ lives. In pursuit of our purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant unmet patient needs. As a spin-off of Theravance, Inc., Theravance Biopharma, Inc. was founded in 2014 and has offices in South San Francisco, and Dublin, Ireland. We are a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines. We invite you to explore our job opportunities and learn more about what Theravance Biopharma has to offer www.theravance.com/join-our-team/our-culture-values. You can also connect with us on Twitter at @TheravanceBio. Please visit www.theravance.com/social-media-guidelines for more information on how to engage with Theravance Biopharma on social media. Open lung disease, rare disease , dysautonomia, neurogenic orthostatic hypotension, biopharma, clinical research, and drug development Open 901 Gateway Blvd. South San Francisco CA US 94080 Theravance Biopharma Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.